[Unfavorable effects of orciprenaline in premature and full-term newborn infants (measurements of arterial acid-base status and blood gases, comparison with xantinol nicotinate)].
D000136:Acid-Base Equilibrium; D001784:Blood Gas Analysis; D001831:Body Temperature; D002245:Carbon Dioxide / Q000097:blood; D006339:Heart Rate; D006801:Humans; D006819:Hyaline Membrane Disease / Q000188:drug therapy; D006863:Hydrogen-Ion Concentration; D007231:Infant, Newborn; D007234:Infant, Premature; D001239:Inhalation; D009921:Metaproterenol / Q000009:adverse effects*; D009539:Nicotinic Acids / Q000627:therapeutic use*; D010100:Oxygen / Q000097:blood; D010101:Oxygen Consumption; D010313:Partial Pressure; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy*; D013806:Theophylline / Q000627:therapeutic use*
D009539:Nicotinic Acids; D002245:Carbon Dioxide; D009921:Metaproterenol; D013806:Theophylline; D010100:Oxygen
Ungünstiger Effekt von Oreiprenalin bei Früh- und Neugeborenen (Arterielle Messungen, Vergleich mit Xanthinol-nicotinat.